Diversification

Diversification in the context of an employer-sponsored 401(k) refers to the strategic practice of spreading investments across a variety of assets within the retirement plan. The primary goal of diversification is to reduce risk and enhance potential returns by not relying on the performance of a single investment. Instead, it involves allocating funds across different asset classes, industries, or regions to create a well-balanced and resilient portfolio.

One example of diversification in a 401(k) would be allocating funds to a mix of stocks, bonds, and cash equivalents. This blend allows investors to benefit from the growth potential of stocks, the stability of bonds, and the liquidity of cash.

Another example is diversifying across different industries. By investing in companies from various sectors such as technology, healthcare, and energy, investors can mitigate the impact of downturns in any specific industry on their overall portfolio performance.

Furthermore, geographic diversification is essential in reducing exposure to regional economic risks. For instance, a 401(k) portfolio diversified across global markets may include investments in both domestic and international assets, helping to balance the impact of economic changes in different countries.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.